These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26165041)

  • 1. [Synoptic report of the American College of Pathologists and the Polish Society of Pathologists - version 2014 ].
    Olszewski W; Chmielik E
    Pol J Pathol; 2014 Dec; 65(4 Suppl 2):S21-31. PubMed ID: 26165041
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does molecular biology play any role in ductal carcinoma in situ?].
    Sakr RA
    Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunohistochemical features of breast fibroadenomas].
    Samoĭlov MV; Bessmertnaia VS; Babichenko II
    Arkh Patol; 2007; 69(4):41-3. PubMed ID: 17926577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
    Kalogeraki A; Garbagnati F; Santinami M; Zoras O
    In Vivo; 2002; 16(2):141-4. PubMed ID: 12073773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion.
    Man YG; Shen T; Weisz J; Berg PE; Schwartz AM; Mulshine JL; Sang QX; Nieburgs HE
    Cancer Detect Prev; 2005; 29(4):323-31. PubMed ID: 16122886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Micrometastases of the axillary lymph nodes in breast cancer. An immunohistochemical study].
    Ronay G; Tomesch A; Tulusan AH
    Pathologe; 1989 Sep; 10(5):289-93. PubMed ID: 2477837
    [No Abstract]   [Full Text] [Related]  

  • 9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can some DCIS patients avoid adjuvant therapy? Still unknown.
    Schmidt C
    J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases.
    Moriya T; Sakamoto K; Sasano H; Kawanaka M; Sonoo H; Manabe T; Ito J
    Mod Pathol; 2000 Jan; 13(1):13-8. PubMed ID: 10658905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCIS: use of biomarkers and morphology to predict concurrent invasion.
    Lagios MD
    Breast J; 2005; 11(1):1. PubMed ID: 15647070
    [No Abstract]   [Full Text] [Related]  

  • 14. College of American Pathologists protocol for the reporting of ductal carcinoma in situ.
    Lester SC; Connolly JL; Amin MB
    Arch Pathol Lab Med; 2009 Jan; 133(1):13-4. PubMed ID: 19123725
    [No Abstract]   [Full Text] [Related]  

  • 15. [Proliferation evaluation by measuring Ki67 in breast neoplasms].
    Vincent-Salomon A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S57-9. PubMed ID: 22054462
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
    Okumura Y; Yamamoto Y; Zhang Z; Toyama T; Kawasoe T; Ibusuki M; Honda Y; Iyama K; Yamashita H; Iwase H
    BMC Cancer; 2008 Oct; 8():287. PubMed ID: 18837981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intraductal extension of primary invasive breast carcinoma treated by breast-conservative surgery].
    Bässler R
    Strahlenther Onkol; 1996 Feb; 172(2):110-1. PubMed ID: 8669044
    [No Abstract]   [Full Text] [Related]  

  • 18. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of intraductal carcinoma with pleomorphic cells.
    Cordoba A; Guerrero-Setas D; Vicente F; Mercado MR; Rodriguez I; Martinez-Peñuela JM
    Pathol Int; 2012 Jul; 62(7):511-2. PubMed ID: 22726073
    [No Abstract]   [Full Text] [Related]  

  • 20. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
    Ballehaninna UK; Chamberlain RS
    J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.